The optimal duration of endocrine therapy in hormone receptor-positive breast cancer

Clin Adv Hematol Oncol. 2021 Jun;19(6):383-404.
No abstract available

MeSH terms

  • Antineoplastic Agents, Hormonal* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Receptor, ErbB-2
  • Receptors, Progesterone
  • Tamoxifen / therapeutic use

Substances

  • Antineoplastic Agents, Hormonal
  • Receptors, Progesterone
  • Tamoxifen
  • Receptor, ErbB-2